Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026

Maze is presenting updated Phase 2 and preclinical data, but no new clinical results.

What the company is saying

Maze Therapeutics is announcing its participation at ASN Kidney Week from October 21–25, 2026, where it will showcase data from its lead programs, MZE829 and MZE782. The company is emphasizing its scientific progress by scheduling an oral presentation on October 24, 2026, covering updated details from the Phase 2 HORIZON trial of MZE829 in APOL1-mediated kidney disease. Two preclinical posters on SLC6A19 inhibition, the mechanism behind MZE782, will be presented on October 22 and 23, 2026. CEO Jason Coloma frames the event as an opportunity to engage the nephrology community and highlight portfolio progress, using language such as 'encouraging clinical activity' and 'commitment to advancing new precision medicines.' The announcement highlights the company's use of its Compass™ platform to pursue genetically validated targets, but does not provide new clinical efficacy or financial data. The overall tone is optimistic and forward-looking, focusing on the pipeline's potential rather than realised milestones.

What the data suggests

The announcement provides specific dates and times for Maze's presentations at ASN Kidney Week, confirming the company's active engagement with the nephrology research community. MZE829 is disclosed as a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease, and MZE782 as a SLC6A19 inhibitor in Phase 2 development with potential applications in phenylketonuria and chronic kidney disease. The HORIZON study is referenced as the source of previously reported, now updated, Phase 2 data for MZE829, but no new efficacy, safety, or biomarker results are disclosed. The two preclinical posters support the mechanistic rationale for SLC6A19 inhibition, but again, no quantitative or clinical outcome data are provided. There are no financial figures, operational metrics, or commercial milestones in this release. The evidence presented is limited to the act of presenting at a conference and the current development stage of the pipeline.

Analysis

The announcement is upbeat in tone, emphasizing Maze Therapeutics' participation in a major nephrology conference and highlighting progress in its pipeline. However, the measurable progress is limited: the company is presenting previously reported Phase 2 data (with some updates) and preclinical research, but no new clinical results, financials, or commercial milestones are disclosed. Most key claims are forward-looking, describing the potential of MZE782 and the company's platform rather than realised outcomes. Phrases like 'encouraging clinical activity' and 'first- or best-in-class potential' are not substantiated with data in this release. The benefits of these programs, if realised, are likely years away, as both lead assets remain in Phase 2 or preclinical stages. There is no mention of large capital outlays or immediate earnings impact, so capital intensity is not flagged. Overall, the narrative slightly overstates the immediacy and certainty of progress relative to the evidence provided.

Risk flags

• ●Maze's lead assets, MZE829 and MZE782, are both in Phase 2 or earlier development, meaning there is substantial clinical, regulatory, and commercial risk before any potential approval or revenue. The absence of new clinical data in this announcement increases uncertainty about the programs' actual efficacy and safety profiles.
• ●The company's claims of 'encouraging clinical activity' and 'first- or best-in-class potential' are not substantiated with quantitative results or comparative data in this release. This reliance on aspirational language without supporting evidence raises the risk that expectations may be ahead of realised progress.
• ●There is no disclosure of financial results, cash position, or funding runway, leaving investors without visibility into Maze's ability to sustain its pipeline through costly late-stage trials. This lack of financial transparency is a material risk for a clinical-stage biotech.

Bottom line

Maze Therapeutics is using ASN Kidney Week to highlight its ongoing Phase 2 and preclinical work on MZE829 and MZE782, but the announcement contains no new clinical results or financial data. The company is still years away from potential commercialisation, and the evidence provided is limited to presentation schedules and pipeline descriptions. Investors should be aware that the narrative is heavily forward-looking and not yet backed by concrete efficacy or safety outcomes. The most important takeaway is that Maze remains in the early-to-mid clinical development phase, with substantial execution and funding risks ahead. The next actionable update will require the release of new clinical trial results or material financial disclosures.

Announcement summary

(NASDAQ:MAZE) Maze Therapeutics, Inc. announced it will present data supporting its lead programs, MZE829 and MZE782, at the American Society of Nephrology (ASN) Kidney Week, held October 21–25, 2026. The company will deliver an oral presentation of previously reported data, updated with additional details from the Phase 2 HORIZON trial evaluating MZE829 in patients with APOL1-mediated kidney disease (AMKD). Maze will also present two preclinical posters highlighting research that further supports SLC6A19 inhibition, the mechanism underlying MZE782, as a potential therapeutic approach for chronic kidney disease (CKD). Jason Coloma, Ph.D., chief executive officer of Maze, stated that ASN Kidney Week is an important opportunity to engage with the nephrology community and highlight progress across the kidney disease portfolio. He noted that the initial HORIZON results for MZE829, reported earlier in the year, demonstrated encouraging clinical activity in patients with AMKD. The oral presentation, titled '[SA-OR053] Evaluation of Safety, Tolerability, and Efficacy of MZE829 in Adults with APOL1-Mediated Kidney Disease (HORIZON Study)', will be delivered by Opeyemi A. Olabisi, M.D., Ph.D., Chief of the Nephrology Division and Associate Professor of Medicine, Duke University School of Medicine, on October 24, 2026, from 5:40 PM to 5:50 PM MT. The first poster, '[FR-PO0215] A New Role for SLC6A19 Inhibition: Reducing Uptake of Nephrotoxins to Limit Kidney Injury', will be presented on October 23, 2026, from 10:00 AM to 12:00 PM MT. The second poster, '[TH-PO0213] SLC6A19 Inhibition Drives a Protective Proximal Tubule Metabolic State Complementary to SGLT2 Inhibition', will be presented on October 22, 2026, from 10:00 AM to 12:00 PM MT. Maze’s pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor in Phase 2 development with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). The company uses its Compass™ platform to pursue genetically validated targets by integrating variant discovery and functionalization to advance small molecule programs with first- or best-in-class potential.

Disagree with this article?